|
Covax
COVID-19 Vaccines Global Access, abbreviated as COVAX, is a worldwide initiative aimed at equitable access to COVID-19 vaccines directed by the GAVI vaccine alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and the World Health Organization (WHO), alongside key delivery partner UNICEF. It is one of the four pillars of the Access to COVID-19 Tools Accelerator, an initiative begun in April 2020 by the WHO, the European Commission, and the government of France as a response to the COVID-19 pandemic. COVAX coordinates international resources to enable Developing country, low-to-middle-income countries equitable access to COVID-19 COVID-19 testing, tests, COVID-19 drug development, therapies, and COVID-19 vaccine, vaccines. UNICEF is the key delivery partner, leveraging its experience as the largest single vaccine buyer in the world and working on the procurement of COVID-19 vaccine doses, as well as logistics, country readiness and in-country delivery. By 19 Oct ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Covaxin
Covaxin (list of pharmaceutical compound number prefixes, development name, BBV152) is a Inactivated vaccine, whole inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology. On 3 November 2021, the World Health Organization (WHO) validated the vaccine for emergency use, as the first Indian-developed covid vaccine to be approved. By 31 January 2022, Covaxin had been granted emergency use approval in 13 countries. Medical uses Effectiveness A vaccine is generally considered effective if the estimate is ≥50% with a >30% lower limit of the 95% confidence interval. Effectiveness is generally expected to slowly decrease over time. Efficacy A phase 3 clinical trial with 25,798 participants found that the vaccine is effective against asymptomatic cases, effective against symptomatic disease, effective against severe disease, and effective against the Delta variant. ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
COVID-19 Vaccine
A COVID19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 ( COVID19). Knowledge about the structure and function of previous coronaviruses causing diseases like severe acute respiratory syndrome ( SARS) and Middle East respiratory syndrome ( MERS) accelerated the development of various vaccine platforms in early 2020. In 2020, the first COVID19 vaccines were developed and made available to the public through emergency authorizations and conditional approvals. However, immunity from the vaccines wanes over time, requiring people to get booster doses of the vaccine to maintain protection against COVID19. The COVID19 vaccines are widely credited for their role in reducing the spread of COVID19 and reducing the severity and death caused by COVID19. Many countries implemented phased distribution plans that prioritized those at highest risk of comp ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Sinopharm BIBP COVID-19 Vaccine
The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, the Sinopharm COVID-19 vaccine, or BIBP vaccine, is one of two Inactivated vaccine, whole inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products (sometimes written as Beijing Bio-Institute of Biological Products, resulting in the two different acronyms BBIBP and BIBP for the same vaccine). It completed Phases of clinical research#Phase III, Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants. BBIBP-CorV shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19. Its product name is SARS-CoV-2 Vaccine (Vero Cell), not to be confused with the similar product name of CoronaVac. Peer-reviewed results published in ''JAMA'' of Phase III trials in United Arab Emirates and Bahrain showed that the vaccine is 78.1% effective against symptomatic cases and 100% ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Gavi, The Vaccine Alliance
GAVI, officially Gavi, the Vaccine Alliance (previously the GAVI Alliance, and before that the Global Alliance for Vaccines and Immunization) is a public–private global health partnership with the goal of increasing access to immunization in poor countries. In 2016, Gavi channeled more than half of total donor assistance for health, and most donor assistance for immunization, by monetary measure. Gavi supports the immunization of almost half the world's children. Gavi has helped immunize over 760 million children, preventing over 13 million deaths worldwide, helping increase diphtheria vaccine coverage in supported countries from 59% in 2000 to 81% in 2019, contributing to reducing child mortality by half. It also seeks to improve the economics of vaccines, negotiating bulk prices, supporting price discrimination, and reducing the commercial risks that manufacturers face when selling vaccines to the poor and developing vaccines. It also provides funding to strengthen ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
CoronaVac
CoronaVac, also known as the Sinovac COVID-19 vaccine, was a whole inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. It was phase III clinically trialled in Brazil, Chile, Indonesia, the Philippines, and Turkey and relies on traditional technology similar to other inactivated-virus COVID-19 vaccines, such as the Sinopharm BIBP vaccine, another Chinese vaccine, and Covaxin, an Indian vaccine. CoronaVac does not need to be frozen, and both the final product and the raw material for formulating CoronaVac can be transported refrigerated at 2–8 °C (36–46 °F), the temperatures at which flu vaccines are kept. A real-world study of tens of millions of Chileans who received CoronaVac found it to be 66% effective against symptomatic COVID-19, 88% effective against hospitalization, 90% effective against ICU admissions, and 86% effective against deaths. In Brazil, after 75% of the population in Serrana, São Paulo, received CoronaVa ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
GAVI
GAVI, officially Gavi, the Vaccine Alliance (previously the GAVI Alliance, and before that the Global Alliance for Vaccines and Immunization) is a Public–private partnership, public–private global health partnership with the goal of increasing access to immunization in poor countries. In 2016, Gavi channeled more than half of total donor assistance for health, and most donor assistance for immunization, by monetary measure. Gavi supports the immunization of almost half the world's children. Gavi has helped immunize over 760 million children, preventing over 13 million deaths worldwide, helping increase DPT vaccine, diphtheria vaccine coverage in supported countries from 59% in 2000 to 81% in 2019, contributing to reducing child mortality by half. It also seeks to improve the economics of vaccines, negotiating bulk prices, supporting price discrimination, and reducing the commercial risks that manufacturers face when selling vaccines to the poor and developing vaccin ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Novavax COVID-19 Vaccine
The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations. Updated versions of the vaccine have been developed to provide coverage against the Omicron variant, with different formulas for 2023–2024 (containing a recombinant spike protein from lineage XBB.1.5) and 2024–2025 (containing recombinant spike protein from lineage JN.1). Medical uses The Novavax COVID19 vaccine is indicated for active immunization to prevent COVID19 caused by SARS-CoV-2. In the US, Nuvaxovid is indicated for active immunization to prevent COVID19 caused by SARS-CoV-2 in adults aged 65 years of age and older. Nuvaxovid is also indicated for individuals aged 12 through 64 years of age who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. Efficacy In December 2021, Novavax reported that its ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Janssen COVID-19 Vaccine
The Janssen COVID19 vaccine, (Ad26.COV2.S) sold under the brand name Jcovden, is a COVID19 vaccine that was developed by Janssen Vaccines in Leiden, Netherlands, and its Belgium, Belgian parent company Janssen Pharmaceuticals, a subsidiary of American company Johnson & Johnson. It is a viral vector vaccine based on a human adenovirus that has been modified to contain the gene for making the coronavirus spike protein, spike protein of the SARS-CoV-2 virus that causes COVID19. The body's immune system responds to this spike protein to produce Antibody, antibodies. The vaccine requires only one dose and does not need to be stored frozen. Clinical trials for the vaccine were started in June 2020, with Phase III trials, phaseIII involving around 43,000 people. In January 2021, Janssen announced that 28 days after a completed vaccination, the vaccine was 66% effective in a one-dose regimen in preventing symptomatic COVID19, with an 85% efficacy in preventing severe COVID19 and 100 ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Oxford–AstraZeneca COVID-19 Vaccine
The Oxford–AstraZeneca COVID19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine COVID-19 vaccine, for the prevention of COVID-19. It was developed in the United Kingdom by University of Oxford, Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee Adenoviridae, adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the Vaccine efficacy, efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the SARS-CoV-2 Alpha variant, Alpha variant (lineage B.1.1.7) and 61% against the SARS-CoV-2 Delta variant, Delta variant (lineage B.1.617.2). The vaccine is stable at refrigerator temperatures and has a good safety prof ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
RNA Vaccine
An mRNA vaccine is a type of vaccine that uses a copy of a molecule called messenger RNA (mRNA) to produce an immune response. The vaccine delivers molecules of antigen-encoding mRNA into cells, which use the designed mRNA as a blueprint to build foreign protein that would normally be produced by a pathogen (such as a virus) or by a cancer cell. These protein molecules stimulate an adaptive immune response that teaches the body to identify and destroy the corresponding pathogen or cancer cells. The mRNA is delivered by a co-formulation of the RNA encapsulated in lipid nanoparticles that protect the RNA strands and help their absorption into the cells. Reactogenicity, the tendency of a vaccine to produce adverse reactions, is similar to that of conventional non-RNA vaccines. People susceptible to an autoimmune response may have an adverse reaction to messenger RNA vaccines. The advantages of mRNA vaccines over traditional vaccines are ease of design, speed and lower cost ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
BioNTech
BioNTech SE ( ; or short for Biopharmaceutical New Technologies) is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases. The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes. In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. History Foundation (2008–2014) BioNTech was founded in 2008 based on research by Uğur Şahin, Özlem Türeci, and Christoph Huber, with a seed investment of €180 million from MIG Capital, a Munich-based venture capital firm, the family office of Andreas and Thomas Strüngmann, ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Antony Blinken
Antony John Blinken (born April 16, 1962) is an American lawyer and diplomat who served as the 71st United States secretary of state from 2021 to 2025. He previously served as Deputy National Security Advisor, deputy national security advisor from 2013 to 2015 and Deputy Secretary of State, deputy secretary of state from 2015 to 2017 under President Barack Obama. Blinken was previously National Security Advisor to the Vice President, national security advisor to then-Vice President Joe Biden from 2009 to 2013. During the Presidency of Bill Clinton, Clinton administration, Blinken served in the United States Department of State, State Department and in senior positions on the United States National Security Council, National Security Council from 1994 to 2001. He was a senior fellow at the Center for Strategic and International Studies from 2001 to 2002. He advocated for the 2003 invasion of Iraq while serving as the Democratic staff director of the United States Senate Committe ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
